MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today announced that it has received clearance from the United States Food and Drug Administration to market its Agento™ IC silver-coated endotracheal tube. The clearance includes claims for the reduction of microbiologically confirmed ventilator associated pneumonia (VAP). Management is currently evaluating the benefits of launching the Agento™ IC product in conjunction with the potential publication of the clinical trial results in a major peer-review medical journal. The product will be marketed by Bard’s Medical division located in Covington, Georgia.
